In modelli sperimentali di diabete, GLP-1 si dimostrato capace di inibire lapoptosi delle cellule e promuoverne la proliferazione attraverso il reclutamento di precursori cellulari, contribuendo cos ad implementare la disponibilit di cellule attive dal punto di vista funzionale [7,8]
However, many receptor-specific interactions were observed
Common Types of Solutions Used for Dilution 1
Szukiewicz D, Stangret A, Ruiz-Ruiz C, et al
Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes
